Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Höllviken – page 80

1 391 clinical trials in Höllviken, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Höllviken at a glance
1 391
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 391 trials in Höllviken

Open in trial search

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Losmapimod
  • Sponsor:Fulcrum Therapeutics Inc.

Myotonic dystrophy

Not recruiting

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:AOC 1001
  • Sponsor:Avidity Biosciences Inc.

Long-term Safety Study of Onasemnogene Abeparvovec for Patients with Spinal Muscular Atrophy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Onasemnogene Abeparvovec
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Mitapivat for Children with Pyruvate Kinase Deficiency Receiving Regular Blood Transfusions

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Study on CLIC-1901 CAR T-cells and Tocilizumab for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clic-1901 Cart
  • Sponsor:Region Hovedstaden

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor

Investigational
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emactuzumab
  • Sponsor:Synox Therapeutics Limited

Emphysema

Not recruiting

Study on Long-term Safety of Weekly Intravenous Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1-Antitrypsin Deficiency

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-ANTITRYPSIN
  • Sponsor:Grifols Therapeutics LLC

Emphysema

Not recruiting

Study on the Effects of Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1 Antitrypsin Deficiency

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-ANTITRYPSIN
  • Sponsor:Grifols Therapeutics LLC

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Höllviken

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on Chronic Obstructive Pulmonary Disease (COPD) management through advanced combination therapy approaches. The studies aim to evaluate triple therapy effectiveness compared to dual bronchodilator treatments for improving cardiopulmonary outcomes.

  • Respiratory Disease Management
  • Cardiopulmonary Health
  • Therapeutic Combinations

These trials explore enhanced treatment options for patients with chronic respiratory conditions, focusing on improving their quality of life through optimized medication combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.